
Newron Starts Phase III ENIGMA-TRS Trial of Evenamide for Treatment-Resistant Schizophrenia
Newron Pharmaceuticals Launches Pivotal Phase III ENIGMA-TRS Program, Randomizing First Patients to Evaluate Evenamide as an Add-On Therapy in Treatment-Resistant Schizophrenia Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical company specializing in therapies for diseases affecting the central and…